IAS (International AIDS Society) Conference

The Latest

Early ART and Testing HIV Negative With Rapid HIV Tests

Very early initiation of ART, followed by several years of viral suppression, can have a relatively common outcome of testing HIV negative using rapid HIV tests.

By Simon Collins for HIV i-Base

What Are the Common HIV Transmission Pathways Among Trans Women?

Many trans women living with HIV may contract the virus because they or their sexual partners are intravenous drug users (IDU), finds a new study.

By Barbara Jungwirth

Trust Gay Men: IPERGAY Finds Zero New Infections, Even With Infrequent Sex

It turns out that you can trust gay men at high risk for HIV to take care of their health -- even if they have to remember to take an HIV prevention pill before sex.

By Heather Boerner

Mosaic Antigens and Mountaineering Metaphors: Climbing Toward the Next HIV Vaccine Efficacy Trial

Janssen Vaccines and Prevention B.V. is now rapidly advancing an experimental prime-boost HIV vaccine regimen, with plans announced to launch a large-scale "proof of concept" efficacy trial in women in late 2017/early 2018.

By Richard Jefferys for Treatment Action Group

Dolutegravir Outperforms Lopinavir/Ritonavir Second-Line: Interim Results From the DAWNING Study

Dolutegravir (DTG) was superior to lopinavir/ritonavir (LPV/r) in a comparison of DTG-based regimen versus the WHO-recommended second-line regimen.

By Polly Clayden for HIV i-Base

PrEP Updates From the 9th International AIDS Society Conference on HIV Science

Brief IAS 2017 summaries of ongoing research on pre-exposure prophylaxis (PrEP), evaluating its long-term effectiveness and safety, patient experiences, and alternative dosing schedules, such as an on-demand regimen.

By Camille Arkell for Canadian AIDS Treatment Information Exchange

MK-8591: Further Compelling Early Results for Both Treatment and Prevention

Two interesting early studies on the investigational NRTI MK-8591 (EFdA) were presented at IAS 2017. This compound is notable for a very high potency, a long-half life and the potential for use both as HIV treatment and for HIV prevention.

By Simon Collins for HIV i-Base

Tenofovir (TDF) Not Tied to Bone Fractures in French Case-Control Study

The findings could inform the debate on the merits of TDF, which is available in many regions as a less-costly generic, versus the more recently approved prodrug tenofovir alafenamide (TAF).

By Roger Pebody

HIV Pipeline Drugs: IAS 2017 Update

A review of HIV drugs in development that summarizes the most exciting new research over the previous year.

By Simon Collins for HIV i-Base

Mosaic HIV Vaccine Candidate Shows Promise in Early-Stage Trial

The vaccine candidate is called a "mosaic" vaccine because it includes snippets from a variety of different HIV subtypes, called clades. It is designed to work globally against most clades.

By Barbara Jungwirth